title: Role of MTHFR (677, 1298) haplotype in the risk of developing secondary leukemia after treatment of breast cancer and hematological malignancies.
abstract: Therapy-related myelodysplasia and acute myeloid leukemia (t-MDS/AML) is a malignancy occurring after exposure to chemotherapy and/or radiotherapy. Polymorphisms involved in chemotherapy/radiotherapy response genes could be related to an increased risk of developing this neoplasia. We have studied 11 polymorphisms in genes of drug detoxification pathways (NQO1, glutathione S-transferase pi) and DNA repair xeroderma pigmentosum, complementation group (3) (XPC(3), X-ray repair cross complementing protein (1)), Nijmegen breakage syndrome (1), excision repair cross-complementing rodent repair deficiency, complementation group (5) and X-ray repair cross complementing protein (3) and in the methylene tetrahydrofolate reductase gene (MTHFR(2), 677C>T, 1298A>C), involved in DNA synthesis. The analyzed groups were a t-MDS/AML patients group (n=81) and a matched control group (n=64) treated similarly, and they did not develop t-MDS/AML. We found no significant differences when the groups were compared globally. However, when analysis was carried out according to the primary neoplasia involved, a significant association was observed between the MTHFR haplotype (single nucleotide polymorphisms 677 and 1298) and the risk of developing t-MDS/AML in the breast cancer patients group (P=0.016) and cyclophosphamide-treated hematological disease group (P=0.005). Risk haplotype was different for each case, corresponding to the 677T1298A haplotype after breast cancer treatment and the 677C1298C haplotype after hematological malignancy treatment. We postulate that such differences are related to variations in chemotherapy schemes between hematological and breast cancers and their differential interaction with the MTHFR route.
authors.affiliation: Servicio de Hematología y Oncología, Hospital Clínico Universitario de Valencia, Universidad de Valencia, Valencia, Spain.
authors.forename: V M
authors.initials: VM
authors.lastname: Guillem
authors.forename: M
authors.initials: M
authors.lastname: Collado
authors.forename: M J
authors.initials: MJ
authors.lastname: Terol
authors.forename: M J
authors.initials: MJ
authors.lastname: Calasanz
authors.forename: J
authors.initials: J
authors.lastname: Esteve
authors.forename: M
authors.initials: M
authors.lastname: Gonzalez
authors.forename: C
authors.initials: C
authors.lastname: Sanzo
authors.forename: J
authors.initials: J
authors.lastname: Nomdedeu
authors.forename: P
authors.initials: P
authors.lastname: Bolufer
authors.forename: A
authors.initials: A
authors.lastname: Lluch
authors.forename: M
authors.initials: M
authors.lastname: Tormo
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects; D001943:Breast Neoplasms / Q000188:drug therapy / Q000473:pathology; D016022:Case-Control Studies; D006239:Haplotypes; D019337:Hematologic Neoplasms / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D007938:Leukemia / Q000139:chemically induced / Q000209:etiology / Q000235:genetics*; D042965:Methylenetetrahydrofolate Reductase (NADPH2) / Q000235:genetics*; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000209:etiology / Q000235:genetics; D020641:Polymorphism, Single Nucleotide; D012307:Risk Factors
chemical_list: D000970:Antineoplastic Agents; D042965:Methylenetetrahydrofolate Reductase (NADPH2)